Anti-Ro52 Antibodies
Anti-Ro52 antibodies are autoantibodies that target the Ro52 protein, which is involved in immune system regulation. Elevated levels of these antibodies are often associated with autoimmune conditions.
Anti-Ro52 antibodies are markers for autoimmune diseases, particularly systemic lupus erythematosus (SLE) and Sjögren's syndrome.
Key facts at a glance
- Units
- U/mL
- Clinical utility
- diagnostic
- Result kind
- qualitative
- FDA-cleared
- Roche Anti-Ro52, Mitocheck Anti-Ro52
Anti-Ro52 antibodies are a type of autoantibody that target the Ro52 protein, a component of the body's immune system. These antibodies are commonly found in patients with autoimmune disorders.
The presence of Anti-Ro52 antibodies is often used to aid in the diagnosis of conditions such as systemic lupus erythematosus (SLE) and Sjögren's syndrome. Elevated levels can indicate an underlying autoimmune condition.
Testing for Anti-Ro52 antibodies is typically done through a blood test. Results are interpreted in the context of other clinical findings and diagnostic criteria.
Frequently asked questions
What is the normal range for Anti-Ro52 antibodies?
What conditions are associated with elevated Anti-Ro52 antibodies?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy